Donovan, House Double Down On Opioid Battle Plan With $1 Billion Investment
Washington, DC—November 30, 2016.... Congressman Dan Donovan (NY-11) and the U.S. House of Representatives today infused the national fight against opioid abuse with $1 billion in grants for states to distribute for treatment, education, and enforcement. The funding is part of the sweeping 21st Century Cures Act, which reforms the drug approval process to accelerate medical breakthroughs and encourage innovation. The bill also dedicates $4.8 billion to the National Institutes of Health to research treatments and cures for deadly diseases, including cancer and Alzheimer’s. The legislation passed the House with broad bipartisan support. The spending is fully offset with savings in other parts of the budget.
Congressman Donovan said, “Congress can’t solve the addiction crisis from Washington, but we can equip the experts on the ground with the tools they need to succeed – and that’s what we did today. Beyond the opioid funding, this landmark legislation will bring our country’s drug approval process into the 21st century and make a down payment on finding cures for the diseases that plague humanity.”
Among other provisions, the bill:
- increases funding for medical research to the National Institutes of Health and the Centers for Disease Control;
- offers new incentives for developing treatments for diseases, including cancer and Alzheimer’s;
- streamlines research and clinical trial procedures; and
- improves the U.S. mental health system.
Donovan concluded, “After losing my mother last year, this legislation is personal to me and to the millions of Americans who’ve watched a loved one suffer from disease. This is a shift in the country’s medical research policies that will hopefully lead to exciting breakthroughs and quicker access to the latest treatments.”
The 21st Century Cures Act – which included input from patients, researchers, and healthcare experts – combines two bills that were previously passed by the U.S. House of Representatives. The bill will now go to the U.S. Senate for consideration.